Adam Zaki on Muck Rack

Adam Zaki

Verified
Long Island
As seen in: CFO, CFO Europe, Industry Dive, Yahoo Finance, Flipboard, Yahoo, EIN News, NewsBreak, Mondaq, Supply Chain Dive, HR Dive, K-12 Dive, Payments Dive and
Covers:  CFO Q&A's, corporate finance, technology, tax, FP&A, M&A, cybersecurity, public and private accounting, regulation, work trends, human capital, multigenerational workforce management, financial crime

Get in touch with Adam

Contact Adam, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Sysdig CFO Karen Walker on scaling without perfection Original

|
By Adam Zaki Verified
| CFO Verified
This audio is auto-generated. Please let us know if you have feedback. Few finance leaders have had a closer view of how the CFO role has changed more than Karen Walker. Before becoming CFO of real-time cloud security company Sysdig, Walker held finance leadership positions at PagerDuty, Uber, Pandora, Virgin America, CBS and more. She has made a career helping companies navigate hypergrowth, IPO preparation, public-market scrutiny and the operational challenges that come with scaling rapidly.
Open in Who Shared View Duplicates (2) Issue with article?

Vertex Pharmaceuticals CFO’s case for thinking like a portfolio manager

|
By Adam Zaki Verified
| CFO Verified
This audio is auto-generated. Please let us know if you have feedback. When Charles Wagner joined Vertex Pharmaceuticals in 2019, the company was preparing for its biggest moment yet. Trikafta, the cystic fibrosis treatment that would later become Vertex's biggest product, was nearing approval. The company also had a pipeline of programs targeting new disease areas, giving leadership confidence that additional growth opportunities could emerge in the years ahead.
Open in Who Shared Issue with article?

Vertex Pharmaceuticals CFO’s case for thinking like a portfolio manager

|
By Adam Zaki Verified
| Yahoo Finance Verified
The comment reflects the realities of drug development. In a recent interview, Vertex CEO Reshma Kewalramani noted that only one out of every 10 projects that begin in the lab ultimately becomes a medicine. Wagner said that dynamic was one reason he felt comfortable joining the company. "Not everything had to go right," he said. "I needed to be able to feel confident that a few things out of 10 were going to go right." Wagner said the same thinking influences how he approaches decision-making.
Open in Who Shared Issue with article?
See all 1,069 licensed articles (1,073 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified